[{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Vaxcyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Expanded Collaboration","leadProduct":"24-Valent Pneumococcal Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Biologics Inc \/ Vaxcyte","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Vaxcyte"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Biologics Inc \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Biologics Inc \/ AstraZeneca"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Biologics Inc \/ Moderna Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Biologics Inc \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Cantrixil","moa":"ERK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Group \/ Oasmia Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Oasmia Pharmaceutical"},{"orgOrder":0,"company":"Lonza Group","sponsor":"PsiVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Agreement","leadProduct":"Ixovex-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Group \/ PsiVac","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ PsiVac"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Lonza Group \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Biologics Inc \/ Humanigen"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Acumen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ Acumen Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Acumen Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Expanded Collaboration","leadProduct":"Sabirnetug","moa":"APP","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"HaemaLogiX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Dexamethasone","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ HaemaLogiX","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Biologics Inc \/ HaemaLogiX"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Capricor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Capricor Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Aruvant Sciences"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Rocket Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Inapplicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Pierre Fabre"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"GC012F","moa":"B cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Gracell Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Triumvira Immunologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"TAC01-HER2","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Triumvira Immunologics","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Triumvira Immunologics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Immunitas Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"IMT-009","moa":"CD161","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Immunitas Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Immunitas Therapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Kodiak Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Antibody-biopolymer Conjugate","year":"2020","type":"Agreement","leadProduct":"Tarcocimab Tedromer","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lonza Biologics Inc \/ Kodiak Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Lonza Biologics Inc \/ Kodiak Sciences"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Dovitinib","moa":"Tyrosine-protein kinase receptor FLT3 | Vascular endothelial growth factor receptor | Stem cell growth factor receptor | Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Nephrology","graph2":"Phase III","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lonza Group \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Group \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"NeuroSense Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Antibiotic","year":"2024","type":"Collaboration","leadProduct":"Ciprofloxacin","moa":"||Bacterial DNA gyrase | Topoisomerase IV","graph1":"Neurology","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Xortx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Xortx Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Xortx Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"2","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"CellPoint","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ CellPoint","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ CellPoint"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"VX-880","moa":"Pancreatic isleT-cell","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Group \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Fred Hutchinson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesothelin TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"6","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Agreement","leadProduct":"ATYR2810","moa":"NRP2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ aTyr Pharma","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Biologics Inc \/ aTyr Pharma"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Leucid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"LEU011","moa":"NKG2D receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Leucid Bio","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Group \/ Leucid Bio"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Lamkap Bio Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"NILK-2301","moa":"CD3\/CEACAM5","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Lamkap Bio Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Lamkap Bio Group"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Pionyr Immunotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"PY265","moa":"MARCO receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Pionyr Immunotherapeutics"},{"orgOrder":0,"company":"Lonza Inc & Lonza America Inc","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Agreement","leadProduct":"CTIM-76","moa":"CLDN-6\/CD3","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lonza Inc & Lonza America Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Inc & Lonza America Inc \/ Lonza Inc & Lonza America Inc","highestDevelopmentStatusID":"5","companyTruncated":"Lonza Inc & Lonza America Inc \/ Lonza Inc & Lonza America Inc"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Affinia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Anc80L65","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Exogenus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2025","type":"Collaboration","leadProduct":"Exo-101","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Exogenus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Exogenus Therapeutics"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Asher Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"AB359","moa":"CD8\/IL-2R","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Asher Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Biologics Inc \/ Asher Biotherapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Surrozen","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Surrozen","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Surrozen"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Altimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"AdCOVID","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lonza Group \/ Altimmune","highestDevelopmentStatusID":"4","companyTruncated":"Lonza Group \/ Altimmune"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Ethris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"ETH52","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lonza Group \/ Ethris","highestDevelopmentStatusID":"2","companyTruncated":"Lonza Group \/ Ethris"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Anthos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Abelacimab","moa":"Coagulation factor XI","graph1":"Hematology","graph2":"Undisclosed","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Biologics Inc \/ Anthos Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Biologics Inc \/ Anthos Therapeutics"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Lonza Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Oceanix","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Lonza Group","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Oceanix","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Lonza Group","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Carnipure","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Iconovo","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lonza Group \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Lonza Group \/ Lonza Group"}]
Find Clinical Drug Pipeline Developments & Deals by Lonza Capsugel
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
